thumbnail image
  • Home
  • About us
    • Company
    • CORE TEAM
    • QUALITY UNIT
    • BUSINESS
  • Services
    • GENERAL TOXICOLOGY
    • DART
    • GENETIC TOXICOLOGY
    • SAFETY PHARMACOLOGY
    • PK/TK
    • EFFICACY STUDY
    • OPHTHALMIC LAB
    • CARCINOGENES
    • Project Management System for Client
  • Laboratories
    • PATHOLOGY LAB
    • CLINICAL LAB
    • BIO-ANALYSIS
    • TEST ARTICLE LAB
  • Animal Welfare
    • Animal welfare
  • News&Events
  • Chinese
  • Home
  • About us
    • Company
    • CORE TEAM
    • QUALITY UNIT
    • BUSINESS
  • Services
    • GENERAL TOXICOLOGY
    • DART
    • GENETIC TOXICOLOGY
    • SAFETY PHARMACOLOGY
    • PK/TK
    • EFFICACY STUDY
    • OPHTHALMIC LAB
    • CARCINOGENES
    • Project Management System for Client
  • Laboratories
    • PATHOLOGY LAB
    • CLINICAL LAB
    • BIO-ANALYSIS
    • TEST ARTICLE LAB
  • Animal Welfare
    • Animal welfare
  • News&Events
  • Chinese
    •    

         

      • Li Wang

      Doctor of Pharmacy

      President

       

      Co-founder of WestChina-Frontier PharmaTech. 30 years' experience in drug safety and efficacy study management, PK/PD study and drug safety evaluation. 10 years' research and work experience in Japan academia. NMPA New Drug Reviewer. Ministry of Health of China Cosmetic Reviewer.

      • Xiaobo Cen

      Doctor of Toxicology

      CEO

         

      Co-founder of WestChina-Frontier PharmaTech. GLP regulation expert. 16 years' experience in drug safety and efficacy study management.

      Research and work experience in Japan academia. NMPA New Drug Reviewer. NMPA New Drug Review Committee External Consultant.


      • Hongxia Li

      Master of Toxicology

      Director of IACUC

       

      Joined WestChina-Frontier PharmaTech early after its inception. GLP regulation expert. Laboratory animal regulation expert.

      Over 30 years' experience in toxicology study management. Research and working experience in North America academia. AAALAC International Inspector. NMPA New Drug Reviewer.

       

      • Hui Zhang

      Doctor of Medicine

      CSO

      Dr. Hui Zhang has worked in pharmaceutical companies such as AstraZeneca and NovoNordisk for 20 Years.

      She is a member of the Society of Toxicology pathology (STP), Society of European Toxicology Pathology (ESTP), Association of Inhalation Toxicology (AIT). She is a committee member of INHAND(International Harmonization of Nomenclature and Diagnostic Criteria) Special Sensory Working Group. Dr. Zhang is the CSO of WCFP as well as the director of pharmacology department.

       

       

       

    • • Bin Liu

      Master of Toxicology

      Deputy General Manager

       

       

      Co-founder of WestChina-Frontier PharmaTech. Expert in domestic and international GLP regulations 18 years' experience in pre-clinical research and drug safety evaluation.
      Working experience in NMPA New Drug Review Committee.

       

       

       

      • Feng Chen

      Doctor of Pharmacy & Transplantation Immunology

      Director of QAU

       

      Joined WestChina-Frontier PharmaTech early after its inception. GLP regulation expert. Over 10 years' experience of QAU

      management. NMPA New Drug Reviewer.

       

       

        

      • Bo Chen

      Doctor of Toxicology

      Director of Toxicology

       

       

      Doctor in Drug and Instrument Evaluatio;CFDA-authorized expert in new drug evaluation ;

      17-year experience as a study director and 5-year management experience of toxicology department;

      Deputy Secretary-General of Reproductive Toxicology

      Committee,Chinese Society of Toxicology.

      • Chunyan Hu

      Pathologist

      Director of Pathology Lab

       

         

      Founder of the WestChina-Frontier PharmaTech pathology team. GLP regulation expert. Over 30 years' experience in clinic

      analysis and pathology analysis management. 10 years' research and work experience in North America academia. NMPA New Drug Reviewer.


      所有文章
      ×
      成都华西海圻医药科技有限公司(English)
      成都华西海圻医药科技有限公司,国家成都新药安全性评价中心
      https://user-assets.sxlcdn.com/images/397921/Fuuup8iHbnSRXKbrJb7f8RgJ3o2r.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png
      Cookie Use
      我们使用cookies来确保流畅的浏览体验。若继续,我们认为你接受使用cookies。
      了解更多